Skip to main content
SpringerLink
Log in

Epithelial Ovarian Cancer

  • Chapter
Tropical Hemato-Oncology

  • 755 Accesses

Abstract

Ovarian cancer is the seventh most common cancer in women worldwide; ovarian cancer is a disease of older women with majority (>80 %) of cases diagnosed in women over 50 years. The median age of patients is somewhat lower in many developing countries because of their population structure. The symptoms of ovarian cancer are nonspecific. Ovarian cancer is not a single entity but represents tumors of epithelial (>90 %), germ cell, or sex cord stromal origin. Ovarian cancer is staged surgically with pathologic confirmation. Appropriate surgery is of paramount importance for correct staging, planning adjuvant treatment, and prognostication. In advanced ovarian cancer, the aim is to achieve optimal cytoreduction, currently defined as complete resection of all disease. The current broad consensus is that paclitaxel-platinum is the standard first-line regimen in advanced ovarian cancer. The various management options for epithelial ovarian cancer based on resource considerations are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. GLOBOCAN (2012) Estimated cancer incidence, prevalence and mortality worldwide in 2012. globocan.iarc.fr/

  2. Bankhead CR, Kehoe ST, Austoker J (2005) Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG 112:857–865

    Article  PubMed  Google Scholar 

  3. Vergote I, De Brabanter J, Fyles A et al (2001) Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357:176–182

    Article  CAS  PubMed  Google Scholar 

  4. Rekhi B, George S, Madur B, Chinoy RF, Dikshit R, Maheshwari A (2008) Clinicopathological features and the value of differential Cytokeratin 7 and 20 expression in resolving diagnostic dilemmas of ovarian involvement by colorectal adenocarcinoma and vice-versa. Diagn Pathol 3:39

    Article  PubMed Central  PubMed  Google Scholar 

  5. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C et al (2003) Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95:113–125

    Article  CAS  PubMed  Google Scholar 

  6. Winter-Roach BA, Kitchener HC, Dickinson HO (2009) Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev (3):CD004706

    Google Scholar 

  7. Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS et al (2010) The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 116:301–306

    Article  PubMed  Google Scholar 

  8. du Bois A, Reuss A, Pujade-Lauraine E et al (2009) Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 115:1234–1244

    Article  PubMed  Google Scholar 

  9. Vergote I, Tropé CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943–953

    Article  CAS  PubMed  Google Scholar 

  10. Kehoe S, Hook J, Nankivell M et al (2013) Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. J Clin Oncol. 31(Suppl):Abstract 5500

    Google Scholar 

  11. Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Shukla NK (2009) Neo-adjuvant chemotherapy in advanced Epithelial Ovarian Cancer (EOC): a prospective, randomized study. Ind J Med Paed Oncol 30(Suppl 1):15

    Google Scholar 

  12. McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6

    Article  CAS  PubMed  Google Scholar 

  13. Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699–708

    Article  CAS  PubMed  Google Scholar 

  14. Muggia FM, Braly PS, Brady MF et al (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18:106–115

    CAS  PubMed  Google Scholar 

  15. Parmar MKB, Adams M, Balestrino M et al (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet 360:505–515

    Article  Google Scholar 

  16. Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–1691

    Article  CAS  PubMed  Google Scholar 

  17. Pignata S, Scambia G, Ferrandina G et al (2011) Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 29:3628–3635

    Article  CAS  PubMed  Google Scholar 

  18. Gordon AN, Teneriello M, Janicek MF, Hines J, Lim PC, Chen MD et al (2011) Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer. Gynecol Oncol 123:479–485

    Article  CAS  PubMed  Google Scholar 

  19. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E et al (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14:1020–1026

    Article  CAS  PubMed  Google Scholar 

  20. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S et al (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15:396–405

    Article  CAS  PubMed  Google Scholar 

  21. Chan J, Brady MF, Penson R, Monk BJ, Boente M, Walker JL et al (2013) Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/− bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). Int J Gynecol Cancer 23(8 Suppl 1):9–10

    Google Scholar 

  22. Hess LM, Benham-Hutchins M, Herzog TJ et al (2007) A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer. Int J Gynecol Cancer 17:561–570

    Article  CAS  PubMed  Google Scholar 

  23. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  CAS  PubMed  Google Scholar 

  24. Burger RA, Brady MF, Bookman MA et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483

    Article  CAS  PubMed  Google Scholar 

  25. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496

    Article  CAS  PubMed  Google Scholar 

  26. Raja FA, Counsell N, Colombo N et al (2012) Platinum combination chemotherapy versus platinum monotherapy in platinum-sensitive recurrent ovarian cancer: a metaanalysis of randomised trials using individual patients data (IPD). Ann Oncol 23:abstr 982P

    Google Scholar 

  27. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302–1308

    Article  CAS  PubMed  Google Scholar 

  29. Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS et al (2015) Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 16:87–97

    Article  CAS  PubMed  Google Scholar 

  30. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC et al (2010) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376:1155–1163

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Tata Memorial Centre, Mumbai, India

    Sudeep Gupta MD, Seema Gulia MD & Amita Maheshwari MD

  2. Department of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada

    Amit M. Oza MD

Authors
  1. Sudeep Gupta MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seema Gulia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amita Maheshwari MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amit M. Oza MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sudeep Gupta MD .

Editor information

Editors and Affiliations

  1. Medical Oncology, Claude-Bernard-Lyon1 University, Lyon, France

    Jean-Pierre Droz

  2. Centre Hospitalier de Cayenne, Cayenne, French Guiana

    Bernard Carme

  3. Service de dermatologie, Centre hospitalier de Cayenne, Cayenne, French Guiana

    Pierre Couppié

  4. Guyane, INSERM CIC 1424, Centre d'Investigation Clinique Antilles, Centre Hospitalier de Cayenne, Cayenne, French Guiana

    Mathieu Nacher

  5. Service d’hémato-oncologie, Hôpital Saint-Louis, Paris, France

    Catherine Thiéblemont

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Gupta, S., Gulia, S., Maheshwari, A., Oza, A.M. (2015). Epithelial Ovarian Cancer. In: Droz, JP., Carme, B., Couppié, P., Nacher, M., Thiéblemont, C. (eds) Tropical Hemato-Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-18257-5_43

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18257-5_43

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-18256-8

  • Online ISBN: 978-3-319-18257-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation